AMGN - AMGEN Inc Stock Analysis
AMGEN Inc (AMGN) is a publicly traded company listed on the . It operates in the industry, part of the broader sector. The company has a market capitalization of 212.56B, generates annual revenue of 38.20B, and reports net income of 8.74B. As of the latest data, the stock is trading at 393.17 USD.
From a valuation and risk perspective, the stock presents the following profile: The stock is moderately valued and aligns with market expectations for established companies. The PEG ratio is above 2, which could imply the stock is overvalued based on its growth outlook. The company is highly leveraged, which may pose risks during economic downturns or periods of rising interest rates. The stock offers a moderate dividend yield (2.57%), which may appeal to income-focused investors. This stock tends to be less volatile than the overall market, often preferred by conservative investors.
Analyst recommendation stands at Hold (3.51), indicating current market sentiment. Institutional ownership is reported at 85.58%, reflecting confidence from large investors. Over the last 12 months, the stock has shown a performance of 40.32%, trading within a 52-week range of 269.77 - 447.03.
AMGN - AMGEN Inc
393.17
Analyst Consensus
Hold 3.51
AMGN – Analyst Rating Summary
- Strong Buy: 6
- Buy: 14
- Hold: 20
- Sell: 2
- Strong Sell: 1
- Total Analysts: 43
| Index: | DJIA, NDX, S&P 500 | P/E: | 24.42 | EPS (ttm): | 16.10 | Insider Own: | 0.24% | Shs Outstand: | 540.60M | Perf Week: | -8.54% |
| Market Cap: | 212.56B | Forward P/E: | 16.10 | EPS next Y: | 24.42 | Insider Trans: | -0.87% | Shs Float: | 539.32M | Perf Month: | -4.33% |
| Income(ttm): | 8.74B | PEG: | 2.86 | EPS next Q: | 5.79 | Inst Own: | 85.58% | Short Float: | 2.23% | Perf Quarter: | 13.72% |
| Revenue(ttm): | 38.20B | P/S: | 5.56 | EPS this Y: | 5.66% | Inst Trans: | 0.00% | Short Ratio: | 4.51 | Perf Half Y: | 4.30% |
| Book/sh: | 21.62 | P/B: | 18.19 | EPS next Y: | 5.81% | ROA: | 9.53% | Short Interest: | 12.04M | Perf Year: | 40.32% |
| Cash/sh: | 25.88 | P/C: | 15.19 | EPS next 5Y: | 5.63% | ROE: | 91.47% | 52W Range: | 269.77 - 447.03 | Perf YTD: | 20.12% |
| Dividend Est.: | 10.10 (2.57%) | P/FCF: | 20.89 | EPS past 3/5Y: | 5.51% 2.93% | ROIC: | 13.76% | 52W High: | 447.03 -12.05% | Beta: | 0.40 |
| Dividend TTM: | 9.94 (2.53%) | Quick Ratio: | 1.13 | Sales past 3/5Y: | 12.09% 7.79% | Gross Margin: | 72.71% | 52W Low: | 269.77 45.74% | Perf 5Y: | 78.01% |
| Dividend Ex-Date: | Aug 21, 2026 | Current Ratio: | 1.37 | EPS Y/Y TTM: | 31.69% | Oper. Margin: | 33.31% | RSI (14): | 36.84 | Volatility: | 2.47% 2.12% |
| Employees: | 31500 | Debt/Eq: | 4.90 | Sales Y/Y TTM: | 9.89% | Profit Margin: | 22.89% | Recom: | 2.50 | Target Price: | 396.46 |
| Option/Short: | Yes / Yes | LT Debt/Eq: | 4.44 | EPS Q/Q: | 64.93% | Payout: | 66.92% | Rel Volume: | 2.56 | Prev Close: | 437.23 |
| Sales Surprise: | 6.66% | EPS Surprise: | 11.97% | Sales Q/Q: | 9.82% | Earnings: | Aug 04 AMC | Avg Volume: | 2.67M | Price: | 393.17 |
| SMA20: | -8.62% | SMA50: | -1.15% | SMA200: | 9.61% | Overbought: -0.84% | Volume: | 6,831,664 | Change: | -10.08% | |
Graham Classic formula value: 285.67
(P/E=8 * 1g) Min value: 197.05
(current P/E * 2g) Max value: 515.83
Average value: 332.85
About AMGEN Inc
Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.
Attention! Trading on the stock market involves financial risks and is not suitable for everyone. The www.stocks-expert.com does not provide financial market trading services; it is for informational purposes only and is not responsible for the consequences of your trading decisions or the operation of the software. Before starting to trade in any markets, make sure you understand the risks associated with trading and that you have a sufficient level of training.